CBI notice to CFO and Company Secretary on financial irregularities

Enforcement RaidRegulatory & Legal View source PDF Explain this filing

VIVIMEDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.9%Reaction day

₹8.38

prior close

₹7.97

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-6.2% vs market

On the reaction day the stock moved 6.2 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-4.9+1.3-6.2

Next day

-9.5+0.3-9.8

-14.0-0.5-13.5

-9.7+2.1-11.8

-14.7+3.1-17.8

-18.9+2.6-21.4

-12.3+0.6-12.9

15d

-7.5-1.4-6.1

-16.0-6.9-9.1

-27.6-7.7-19.9

-16.6+7.0-23.5

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vivimed Labs' CFO and Company Secretary received a CBI notice dated January 27, 2026, from the Banking Securities Fraud Branch in Bengaluru, delivered by email on January 29. The notice follows a complaint by State Bank of India, IFB Branch Hyderabad, regarding financial irregularities. Earlier, Rare ARC had acquired SBI's financial assets of the company along with recovery rights.

Likely market impact

CBI probe into financial irregularities is negative for the stock. May increase legal uncertainty for the company and its investors.